Sunitinib and pazopanib are both standard first-line therapies for clear-cell metastatic renal-cell carcinoma (mRCC). Everolimus is a well-established second-line treatment.
To estimate the efficacy and safety of second-line everolimus following pazopanib or sunitinib.
SUNPAZ was an open-label, phase 4 clinical trial of everolimus in patients with clear-cell mRCC progressing after first-line sunitinib or pazopanib. The primary end point was the number of patients without progression 6 months after starting everolimus. Secondary end points included progression-free survival (PFS), overall survival (OS), and overall response rate. Enrollment was terminated early due to slow recruitment; all analyses are descriptive.
Patients who received prior sunitinib (n = 16) or pazopanib (n = 13) were enrolled. One of 12 patients in the sunitinib group and 6/13 patients in the pazopanib group were progression-free by month 6 in the full analysis set. Median PFS in the sunitinib and pazopanib groups was 2.8 and 8.0 months, and median OS was 14.8 months and 20.4 months, respectively. Fifteen patients in the sunitinib group and 13 in the pazopanib group experienced adverse events.
Safety and efficacy results confirm the second-line everolimus profile. However, baseline differences in patient populations should be taken into consideration.
Urologia internationalis. 2019 Nov 14 [Epub ahead of print]
Martin Schostak, Patrick de Geeter, Thomas Decker, Anna Resch, Claudia Quiering, Stephan Schmitz
Department of Urology and Pediatric Urology, University Hospital Magdeburg, Magdeburg, Germany, ., Department of Urology, Klinikum Kassel GmbH, Kassel, Germany., Practice for Hematology and Oncology, Ravensburg, Germany., Freelancer on behalf of Novartis Pharma GmbH, Nuremberg, Germany., Novartis Pharma GmbH, Nuremberg, Germany., Practice for Oncology and Hematology, Cologne, Germany.